Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221402 · ClinicalTrials.gov registry record · Phase 2
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
A Phase 2 study, sponsored by North Texas Veterans Healthcare System.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01221402 is a Phase 2 study that has completed, run by North Texas Veterans Healthcare System. The registered enrollment target is 38 participants.
The verdict
NCT01221402, a Phase 2 study, has completed, sponsored by North Texas Veterans Healthcare System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Intermediate saphenous vein graft (SVG) lesions are common, have high rates of progression to severe lesions or occlusion, and are associated with high incidence of adverse clinical outcomes. The ALPINE-SVG trial is a randomized-controlled trial of extended-release niacin vs. placebo in patients with intermediate saphenous vein graft lesions. The main hypothesis of the study is that compared to placebo, niacin administration will result in reduction in percent atheroma volume at 12-month follow-up angiography.
Interventions
- DRUG extended-release niacin (Niaspan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221402
The ClinicalTrials.gov registry entry for NCT01221402 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Texas Veterans Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which extended-release niacin (Niaspan) is the first listed.
NCT01221402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01221402 about?
NCT01221402 is a clinical study titled "Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis". Intermediate saphenous vein graft (SVG) lesions are common, have high rates of progression to severe lesions or occlusion, and are associated with high incidence of adverse clinical outcomes. The ALPINE-SVG trial is a randomized-controlled trial of extended-release niacin vs. placebo in patients wi...
What is the current status of trial NCT01221402?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2010-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01221402?
The interventions under investigation include: extended-release niacin (Niaspan) (DRUG).
Who is sponsoring clinical trial NCT01221402?
This trial is sponsored by North Texas Veterans Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.